This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Dexcel Pharma Technologies Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Maxim Gomberg - Innovator in Pharmaceutical Formulations
Introduction
Maxim Gomberg is an inventor based in Jerusalem, Israel. He is currently associated with Dexcel Pharma Technologies Ltd., where he focuses on developing innovative pharmaceutical formulations. Despite having no granted patents to his name, his contributions to the field of pharmaceutical technology are noteworthy.
Latest Patent Applications
Maxim Gomberg has submitted several patent applications, including:
1. **Stable Benzimidazole Formulation** - This application describes an omeprazole delayed release tablet that comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.
2. **Stable Benzimidazole Formulation** - This application outlines a benzimidazole formulation that lacks an intermediate layer while remaining stable during storage and passage through the stomach. It also features low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
Conclusion
Maxim Gomberg is a dedicated inventor whose work in pharmaceutical formulations holds promise for future advancements in the industry. His latest patent applications reflect his commitment to innovation in drug delivery systems.